Key Highlights
- The women’s health technology company transitioned to private ownership on April 7, 2026, through a Blackstone-TPG buyout valued at up to $79 per share.
- Shareholders obtained $76 in immediate cash compensation alongside a conditional value right potentially worth $3 per share based on Breast Health division performance.
- Abu Dhabi Investment Authority and GIC provided minority capital for the transaction.
- Stephen MacMillan stepped down after leading the organization for over a dozen years; Joe Almeida assumed the chief executive position.
- Trading of HOLX shares concluded, with delisting proceedings underway at Nasdaq.
The women’s health technology firm concluded its journey as a publicly traded entity on April 7, 2026, wrapping up its acquisition by investment funds operated by Blackstone and TPG with a per-share valuation reaching up to $79.
The buyout agreement, initially revealed to the market on October 21, 2025, secured stockholder backing on February 5, 2026. The deal structure incorporated minority stakes from an Abu Dhabi Investment Authority subsidiary and a GIC affiliate.
Investors obtained immediate payment of $76 per share in cash. Additionally, they acquired a non-transferable contingent value right with potential value reaching $3 per share — distributed across two equal payments of up to $1.50 — contingent upon the company achieving specific worldwide revenue benchmarks within its Breast Health division during fiscal years 2026 and 2027.
The conditional value right mechanism establishes that reaching the complete $79 per share valuation depends entirely on meeting those revenue objectives. This element deserves attention from observers monitoring the transaction’s ultimate worth.
Prior to the transaction’s completion, the company generated $4.13 billion in revenue across the trailing twelve months, maintained a gross profit margin of 60%, and posted a current ratio exceeding 4. The firm’s market capitalization stood at $16.97 billion.
The organization’s latest quarterly financial performance came in below Wall Street projections. Revenue totaling $1.05 billion underperformed the $1.07 billion consensus estimate, while adjusted EPS of $1.04 missed the anticipated $1.09 figure.
Executive Suite Transformation
Stephen MacMillan concluded his tenure as chief executive at the deal’s closing, wrapping up more than twelve years leading the organization. Joe Almeida assumes the Chief Executive Officer role with immediate effect and has been appointed as the sole board director.
Almeida brings extensive medical technology sector experience to the position. His career includes serving as Chairman, President and CEO of Baxter International from 2016 through early 2025, and previously holding identical leadership roles at Covidien prior to Medtronic’s 2015 acquisition.
The executive transition demonstrates the new ownership’s strategic vision — Blackstone, overseeing $1.3 trillion in assets, and TPG, managing $303 billion — focused on expansion under private equity stewardship.
The company’s equity framework underwent comprehensive restructuring as part of the transaction. Stock options and equity compensation received treatment through a combination of cash settlements and CVR-linked distributions, while out-of-the-money options received no compensation and were terminated.
Departure from Public Trading
HOLX common shares have concluded trading activity. The organization will complete its delisting from Nasdaq, transforming into a fully controlled subsidiary of the Blackstone-TPG partnership.
The equity closed at $76.01 during its final trading session — virtually matching its 52-week peak of $76.07, demonstrating how accurately the market anticipated the deal’s finalization.
Six financial analysts adjusted earnings projections downward for future periods before the closing. The final analyst recommendation on HOLX carried a Buy rating with an $83 price objective.
InvestingPro awarded the company a “GREAT” financial health assessment before the transaction’s completion.
